$0.627
-0.130 (-20.68%)收盤時
- High
- 0.850
- Open
- 0.790
- VWAP
- 0.68
- Vol
- 942.22K
- Mkt Cap
- —
- Low
- 0.574
- Amount
- 644.26K
- EV/EBITDA, TTM
- 5.50
LakeShore Biopharma Co Ltd, formerly YS Biopharma Co Ltd, is a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The Company's vaccine product YSJATM rabies vaccine has been commercialized. The Company also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
估值指標
事件時間軸
資訊
2.009-22PRnewswireLakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting
- 7.009-12PRnewswire
LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq
- 8.509-10PRnewswire
LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
- 8.508-28PRnewswire
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee
8.508-18NASDAQ.COMLakeShore Biopharma Gets Proposal from Oceanpine Capital
LSB FAQ — answered by Alphio AI
LakeShore Biopharma Co Ltd, formerly YS Biopharma Co Ltd, is a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The Company's vaccine product YSJATM rabies vaccine has been commercialized. The Company also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。